CA
NZ
UK
AU
IND
US
Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotech focused on rare paediatric lysosomal storage disorders, has a market capitalisation of about $99.7 million on 49.85 million shares. The company has said it expects to start its SOTERIA Phase 2 basket trial in the second half …
Healthcare Services Group, Inc. (NASDAQ:HCSG), a provider of housekeeping, laundry and dining services to healthcare facilities, has a market value of roughly $1.42 billion. With the company due to report third-quarter results on October 21 and a freshly announced acquisition in the news, the …
ICON plc (NASDAQ:ICLR), the Dublin-based contract research organisation, reported second-quarter 2026 results that combined soft profitability with strong demand indicators. Adjusted diluted EPS fell to $2.56 from $3.52 a year earlier, yet gross bookings grew 24.1% and the backlog reached $23.4 billion. The focus …
InfuSystem Holdings, Inc. (NYSE American:INFU), a provider of infusion pumps and related services, has a market capitalisation of about $270 million. The company reported record second-quarter 2026 revenue and has announced a sizeable repurchase programme, so this story concentrates on operating and capital-allocation themes.
iSpecimen Inc. (NASDAQ:ISPC), operator of an online marketplace connecting life-science researchers with biospecimen holders, has a shareholder vote on a reverse stock split open until October 30. The company has a market capitalisation of about $2.85 million. Alongside the vote, it has been raising …
Medpace Holdings, Inc. (NASDAQ:MEDP) has a market value of about $17.31 billion and reports third-quarter 2026 results on October 21 after the market close. The angle is company-specific: the interaction between record bookings, cancellation rates and a year of volatility. Several analysts have recently …
DLH Holdings Corp. (NASDAQ:DLHC), a provider of technology-enabled health and human services to U.S. federal agencies, reported a sharply lower fiscal third quarter on July 29, 2026. Revenue nearly halved, a large tax-related charge pushed the company to a net loss, and management signalled …
enGene Therapeutics Inc. (NASDAQ:ENGN) is a clinical-stage biotechnology company developing detalimogene, a non-viral gene therapy for non-muscle invasive bladder cancer. Investors may be looking ahead to a cluster of fourth-quarter milestones, including updated pivotal data and the start of a Biologics License Application (BLA) …
Evolent Health, Inc. (NYSE:EVH) is in focus as it heads toward its third-quarter report, which the company announced on October 9, 2026 it will release on November 5. The company has a market capitalisation of about $480 million. Management raised its 2026 revenue guidance …
Fortrea Holdings Inc. (NASDAQ:FTRE), a contract research organisation serving drug developers, is attracting differing analyst opinions as it heads toward third-quarter results. It has a market capitalisation near $1.96 billion. Recent rating changes, from a Barclays upgrade to Overweight to a BofA Underperform, suggest …
Please wait processing your request...